New York Life Investment Management LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 9,019 shares of the company’s stock, valued at approximately $1,271,000.
Other institutional investors have also recently made changes to their positions in the company. Keating Financial Advisory Services Inc. bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at about $30,000. Allworth Financial LP acquired a new position in shares of Protagonist Therapeutics during the second quarter worth approximately $31,000. Quantbot Technologies LP acquired a new stake in Protagonist Therapeutics in the 2nd quarter valued at $42,000. Parallel Advisors LLC increased its stake in Protagonist Therapeutics by 205.9% during the 3rd quarter. Parallel Advisors LLC now owns 361 shares of the company’s stock valued at $51,000 after purchasing an additional 243 shares in the last quarter. Finally, Harbor Investment Advisory LLC bought a new stake in Protagonist Therapeutics during the 2nd quarter valued at $89,000. Institutional investors and hedge funds own 98.63% of the company’s stock.
Insider Activity
In related news, CFO Asif Ali sold 58,629 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company’s stock, valued at approximately $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 63,548 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the transaction, the chief executive officer directly owned 522,968 shares in the company, valued at approximately $76,447,462.24. The trade was a 10.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 183,629 shares of company stock valued at $26,552,987. 5.19% of the stock is owned by corporate insiders.
Protagonist Therapeutics Price Performance
NASDAQ:PTGX opened at $130.95 on Monday. The company has a market capitalization of $8.55 billion, a P/E ratio of 27.74 and a beta of 1.21. The business has a fifty day simple moving average of $140.30 and a two-hundred day simple moving average of $119.11. Protagonist Therapeutics, Inc. has a 1 year low of $77.00 and a 1 year high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. The business had revenue of $274.41 million for the quarter, compared to analysts’ expectations of $238.49 million. As a group, analysts anticipate that Protagonist Therapeutics, Inc. will post 5.52 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have commented on the company. Weiss Ratings raised Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. Leerink Partners began coverage on shares of Protagonist Therapeutics in a research note on Monday, October 12th. They issued an “outperform” rating and a $190.00 target price for the company. Wolfe Research reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, August 31st. Wedbush reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, November 9th. Finally, UBS Group restated a “buy” rating on shares of Protagonist Therapeutics in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the stock. According to MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $166.67.
Read Our Latest Analysis on Protagonist Therapeutics
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
See Also
- Five stocks we like better than Protagonist Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
